Moperone (original) (raw)

From Wikipedia, the free encyclopedia

Chemical compound

Moperone
Clinical data
Trade names Luvatren (discontinued)
ATC code N05AD04 (WHO)
Legal status
Legal status BR: Class C1 (Other controlled substances)[1]
Identifiers
IUPAC name 1-(4-fluorophenyl)-4-[4-hydroxy-4-(4-methylphenyl)piperidin-1-yl]butan-1-one
CAS Number 1050-79-9
PubChem CID 4249
DrugBank DB13554
ChemSpider 4100
UNII OU730881W5
KEGG D02623
CompTox Dashboard (EPA) DTXSID6049062 Edit this at Wikidata
ECHA InfoCard 100.012.625 Edit this at Wikidata
Chemical and physical data
Formula C22H26FNO2
Molar mass 355.453 g·mol−1
3D model (JSmol) Interactive image
SMILES CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
InChI InChI=1S/C22H26FNO2/c1-17-4-8-19(9-5-17)22(26)12-15-24(16-13-22)14-2-3-21(25)18-6-10-20(23)11-7-18/h4-11,26H,2-3,12-16H2,1H3Key:AGAHNABIDCTLHW-UHFFFAOYSA-N

Moperone (Luvatren, since discontinued) is a typical antipsychotic of the butyrophenone class[2] which is marketed in Japan for the treatment of schizophrenia. It is an antagonist for the D2 (Ki 0.7–1.9 nM), D3 (Ki 0.1–1 nM), and 5-HT2A (Ki 52 nM) receptors. It also has a high binding affinity for the sigma receptors.[3][4]

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Gross H, Kaltenbäck E (1969). "The clinical position of moperone among the butyrophenones". Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry. 23 (1): 4–9. doi:10.3109/08039486909132154. PMID 5354545.
  3. ^ Miyamoto S (2010). "Moperone". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 798. doi:10.1007/978-3-540-68706-1_1838. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
  4. ^ Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 21 March 2022.